Management of co-infection with HIV and TB
Author(s) -
Robert Colebunders
Publication year - 2002
Publication title -
bmj
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.831
H-Index - 429
ISSN - 0959-8138
DOI - 10.1136/bmj.324.7341.802
Subject(s) - tuberculosis , medicine , human immunodeficiency virus (hiv) , antiretroviral therapy , developing country , active tuberculosis , isoniazid , mycobacterium tuberculosis , cause of death , immunology , intensive care medicine , viral load , disease , economic growth , pathology , economics
About a third of the 36 million people living with HIV worldwide are co-infected with mycobacterium tuberculosis; 70% of those co-infected live in sub-Saharan Africa.1 In developing countries half of people with HIV infection will develop active tuberculosis; in some countries in sub-Saharan Africa more than 70% of patients with active tuberculosis are also HIV seropositive.1 Tuberculosis is the leading cause of death among people with HIV infection, accounting for a third of deaths due to AIDS world wide.2 The introduction of highly active antiretroviral therapy has decreased death and opportunistic infections by 60% to 90% among people living with HIV in affluent countries,3 but in developing countries highly active antiretroviral therapy is available to a tiny minority of those who need it. Today there is a shocking inequality worldwide in the prognosis of HIV and tuberculosis co-infection, and it depends on whether patients or their country have access to highly active antiretroviral therapy.Many regimens have been proposed for treating latent tuberculosis infection; the preferred option is still isoniazid, recommended for nine months.4 In settings …
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom